RFK Jr.’s Vaccine Policies Face Legal Challenge & RSV Shot Scrutiny

The future of a new tool to protect babies from a dangerous virus is in question as the Food and Drug Administration reviews its safety. The agency’s scrutiny of the RSV shots – monoclonal antibodies designed to prevent severe illness – comes as Health and Human Services Secretary Robert F. Kennedy Jr. Continues to reshape federal vaccine policy, raising concerns among infectious disease experts.

Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. But for infants, RSV can be severe, leading to bronchiolitis and pneumonia, and is the most common reason babies end up in the hospital during their first year of life. Two new monoclonal antibody treatments have offered a significant breakthrough in preventing severe RSV illness in infants, with studies showing approximately 80% effectiveness at preventing hospitalization. More than half of U.S. Infants have received one of these shots, according to a February survey by the Centers for Disease Control and Prevention.

However, in December, the FDA announced a review of the safety of these monoclonal antibodies, prompted by reports of adverse reactions, including fevers, seizures, and some deaths following vaccination. This move has alarmed many in the medical community, who fear it could undermine a successful public health intervention.

What’s Behind the FDA Review?

The FDA has not publicly detailed the specific concerns driving the review, stating only that It’s evaluating reports of adverse events. Some, like Brian Hooker, chief medical officer for the Children’s Health Defense, a group critical of vaccine safety, believe a more thorough examination of the safety profile is warranted, particularly for vulnerable infants. “I am concerned about the safety of these products,” Hooker said.

However, many experts suspect the review is linked to the broader policy shifts underway at the Department of Health and Human Services under Secretary Kennedy. Kennedy has publicly expressed skepticism about vaccines and has initiated changes to federal vaccine programs, including a recent, temporarily blocked attempt to cut funding for federally backed childhood vaccines. Dr. Sean O’Leary, an assistant professor of pediatrics at the University of Colorado and chair of the American Academy of Pediatrics’ infectious disease committee, believes the FDA’s review is part of a pattern. “It’s more of the same. It’s falsely promoting these safety risks that aren’t real in the name of continuing to try to dismantle the U.S. Vaccination program,” O’Leary said.

What Do the Manufacturers Say?

Both Sanofi and Merck, the companies that manufacture the RSV monoclonal antibodies, are cooperating with the FDA’s review. They maintain that the shots are very safe and that the reported adverse events are not causally linked to the immunization. Sanofi’s Ayman Chit emphasized that no deaths during clinical studies were linked to the shot, and the FDA’s analysis reached the same conclusion. “As a father myself and as someone who leads our medical affairs group, the death of any child is a tragedy,” Chit said. “But no deaths during our clinical studies were linked to the immunization. And This represents not only our conclusion, the FDA itself in analyzing all of our data has reach to the same conclusion.”

Merck’s Paula Annunziata echoed this sentiment, expressing concern that restrictions on the shots could deprive infants of vital protection. “I think it would be such a terrible shame if infants in the United States no longer had protection from RSV,” Annunziata said. “I think that would be horrible.”

How Do These Shots Work?

The new RSV shots are not traditional vaccines. Instead, they deliver laboratory-made antibodies – monoclonal antibodies – that directly fight the virus. These antibodies provide immediate protection to the baby, mimicking the immune response that would naturally develop after exposure to the virus. This approach is particularly beneficial for newborns, who have immature immune systems and are most vulnerable to severe RSV illness. The CDC describes these as a way to “provide babies with passive immunity to protect them from RSV.”

What’s Next?

The FDA has not provided a timeline for completing its safety review. The outcome of the review could range from reaffirming the safety and efficacy of the shots to issuing warnings, restricting their use, or even recalling them from the market. The situation is further complicated by ongoing debates over the federal Vaccine Injury Compensation Program, with some advocating for expanding the conditions eligible for compensation, a move that could potentially destabilize the vaccine market. Aaron Siri, an attorney critical of vaccine mandates, recently petitioned Secretary Kennedy to add over 300 conditions to the Vaccine Injury Table.

For now, public health experts are urging parents to discuss the risks and benefits of RSV immunization with their pediatricians. The CDC continues to recommend the shots for all infants under 8 months of age during RSV season.